Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 460.0% in October

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 16,800 shares, a growth of 460.0% from the September 30th total of 3,000 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average daily volume of 16,800 shares, the short-interest ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a report on Tuesday, August 20th.

Xenetic Biosciences Stock Performance

Shares of Xenetic Biosciences stock traded up $0.08 during trading on Friday, hitting $3.80. 4,287 shares of the stock traded hands, compared to its average volume of 19,854. The stock has a market cap of $4.93 million, a P/E ratio of -1.24 and a beta of 2.25. The company has a fifty day moving average price of $3.93 and a two-hundred day moving average price of $3.95. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.83). The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.54 million. Xenetic Biosciences had a negative net margin of 186.39% and a negative return on equity of 51.05%. On average, equities research analysts expect that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.